Back

Long-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia

28 August 2026 (08:33 - 08:57)
Organised by: Logo
Congress Presentation Part of: Innovations in lipid lowering and cardiometabolic disease Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on next generation cardiometabolic pharmacology: from lipids to RNA therapeutics
Associate Professor A. Navar (Dallas, US)
Video
Presentation thumbnail
HTD1801 as a multisystem cardio‑kidney‑metabolic therapy in type 2 diabetes: phase 3 SYMPHONY Trials demonstrate early CKM risk modification
Doctor F. Surmont (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Ticalicibart monthly as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 TIMER trial
Doctor C. Xu (CN) Doctor T. Li (Xi'an, CN)
Abstract Video

Access the full session

Session thumbnail
Innovations in lipid lowering and cardiometabolic disease
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 08:33 CET
You may be interested in
thumbnail
Congress Presentation
Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: the Essence-TIMI 73b trial
30 August 2025
thumbnail
Congress Presentation
FOURIER-OLE: Primary Results.
29 August 2022
thumbnail
Congress Session
European Heart Journal - Desmond Julian Award
26 August 2023
thumbnail
Congress Presentation
Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources